Listen on the go
CORRECT!
Next Step
touchONCOLOGY touchONCOLOGY
    • FILTER YOUR SEARCH
    Content Type:
    Speciality:
    More Specialities
    Conference:
    More Conferences

    • Dermatological Cancers

    An Introduction to Dermatological Cancers

    The past decade has seen significant advances in the treatment landscape of melanoma. Therapies targeting the BRAF oncoprotein pathway and the development of immunotherapies have transformed the standard of care for patients.

    Expert video highlights and insights from the conference hub and comprehensive peer-reviewed articles from our journal portfolio provide updates on the changing treatment landscape. To learn more about how the latest developments impact on patient outcomes view our expert-led learning activities.

    Dermatological Cancers Content

    Dermatological Cancers, Sarcoma
    FUTURE LEADERS: Shaping the future of melanoma and sarcoma with Dr Rodrigo Munhoz

    “While groundbreaking treatments are transformative, patients often remember the kindness and humanity of their oncologist more than the medicine they receive” Introducing our Future Leaders series, in this interview Dr Rodrigo Munhoz (Oncology Center – Hospital Sírio-Libanês in São Paulo, Brazil) shares his journey into oncology, offering insights into the motivations that inspired him to […]

    Dermatological Cancers, Immunotherapy
    Watch Time: 33 mins
    touchEXPERT OPINIONS
    Navigating treatment choices in high-risk early-stage melanoma
    CE/CME ACCREDITED Dr Teresa Amaral, Prof. Piotr Rutkowski, Dr Tina Hieken Translations available:

    Hear expert insights on recurrence risk in early-stage melanoma and possible treatment approaches

    Learning objectives
    Learning Objectives
    • Recognize various prognostic indicators for predicting high-risk recurrence in patients with early-stage melanoma and their impact on clinical decision-making
    • Evaluate the latest data on immuno-oncology therapy in the adjuvant setting for melanoma stages IIB/C and how advances may affect clinical practice
    • Interpret recent data for neoadjuvant therapy and the role of biomarkers in developing sequential treatment plans for patients with early-stage melanoma
    Breast Cancer, Dermatological Cancers, Lung Cancer, Renal Cancer
    ESMO Congress 2024 – 13 – 17 September, Barcelona Spain

    We’re looking forward to the ESMO Congress 2024 which is taking place in Madrid between 13- 17  September, 2024. Promising attendees an opportunity to explore the latest technologies, treatments, and products in the field of oncology, we are excited to provide independent, expert video coverage of key data. You can sign up here to receive […]

    Breast Cancer, Dermatological Cancers, Gastrointestinal Cancers, Genitourinary Cancer, Gynaecological Cancers, Haematological Malignancies, Haematology, Head and Neck Cancer, Immunotherapy, Lung Cancer, Endocrine Cancers, Paediatric Oncology
    Space medicine: Can microgravity transform pharmaceutical manufacturing?
    Katie King

    In our latest episode, we delve into the world of space medicine to explore how drug crystallization in microgravity could revolutionize biologic drug administration. Joining us is Dr Katie King, CEO of BioOrbit, to discuss the science, challenges, and technological advancements that could make space-based drug production a reality.

    Breast Cancer, Dermatological Cancers, Gastrointestinal Cancers, Gynaecological Cancers, Leukaemia, Lung Cancer
    Foreword – touchREVIEWS in Oncology & Haematology, Volume 20, Issue 1, 2024
    Axel S Merseburger

    Welcome to the latest issue of touchREVIEWS in Oncology & Haematology. We are honoured to present a series of compelling articles that reflect cutting-edge developments and diverse perspectives in this ever-evolving field. This issue includes a series of editorials and reviews from esteemed experts who provide insights into novel therapies and their potential to change […]

    Dermatological Cancers
    Immunotherapeutic Advances in the Treatment of Merkel Cell Carcinoma
    Ruben J Cruz-Chamorro, Alberic Gan, John M Bryant

    touchREVIEWS in Oncology & Haematology. 2024;20(1):32–35

    Merkel cell carcinoma (MCC) is a rare, poorly differentiated and highly aggressive neuroendocrine cutaneous cancer with a high propensity to grow rapidly and metastasize early. Merkel cell polyomavirus (MCPyV) is now estimated to be the causative factor in up to 80% of MCC cases.1 Meanwhile, the remaining 20% are attributed to significant exposure to ultraviolet radiation.2 The […]

    touchMEETING HIGHLIGHTS
    Connecting Symptoms to Quality of Life: The Importance of Considering Patient Wellbeing when Managing Cutaneous T-Cell Lymphoma (CTCL)
    For HCPs in: countries where mogamulizumab is licensed
    View Time: 37 mins Sponsored content

    Healthcare professionals are asked to report any adverse events via their national reporting system (see Section 4.8 of SmPC). In the UK reporting forms and information can be found at https://yellowcard.mhra.gov.uk
    or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Kyowa Kirin Ltd on +44 (0)1896 664000, email: medinfo@kyowakirin.com

    Prescribing Information here

    KKI/INT/MOG/0966
    Date of Preparation: November 2023
    Dermatological Cancers
    Developed by Touch
    Ryan Sullivan, AACR 2023: The STARBOARD phase III trial, encorafenib, binimetinib and pembrolizumab as a combination therapy for BRAF V600 mutant melanoma
    Watch Time: 8 mins

    The STARBOARD trial will investigate encorafenib, binimetinib and pembrolizumab as a combination therapy for BRAF V600 mutant melanoma. In this touchONCOLOGY interview, we speak with Dr Ryan Sullivan (Mass General Cancer Center, Boston, MA, USA) to discuss the mechanisms of encorafenib, binimetinib and pembrolizumab, as well as details on the STARBOARD trial. The presentation entitled […]

    Dermatological Cancers
    Developed by Touch
    Ryan Sullivan, AACR 2023: Current therapeutic options for BRAF V600 mutated melanoma
    Watch Time: 3 mins

    Multiple therapies that have been approved for the treatment of BRAF V600 mutated melanoma. In this touchONCOLOGY interview, we speak with Dr Ryan Sullivan (Mass General Cancer Center, Boston, MA, USA) to discuss the current treatment paradigm and its limitations. Ryan Sullivan presented an abstract entitled ‘Randomized phase 3 study (STARBOARD) evaluating encorafenib (enco) + […]

    Journal articles and more to your inbox

    Get the latest clinical insights from touchONCOLOGY

    Sign me up!
    Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72
    Close Popup